Lloyd Paul Aiello

List of Publications by Year in Descending Order

39 papers	2,951 citations	25 h-index	40 g-index
40 ext. papers	3,638 ext. citations	6.7 avg, IF	4.9 L-index

#	Paper	IF	Citations
39	Association of Cognitive Function and Retinal Neural and Vascular Structure in Type 1 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1139-1149	5.6	10
38	Retinal Vascular Caliber Association with Nonperfusion and Diabetic Retinopathy Severity Depends on Vascular Caliber Measurement Location. *Ophthalmology Retina*, **2021**, 5, 571-579	3.8	0
37	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. *Ophthalmology*, **2021**, 128, 554-560	7.3	2
36	Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. *Science Translational Medicine*, **2019**, 11,	17.5	27
35	One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study. *Ophthalmology Retina*, **2019**, 3, 1107-1109	3.8	9
34	Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. *JAMA Ophthalmology*, **2019**, 137, 65-73	3.9	60
33	Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. *Ophthalmology*, **2018**, 125, 1054-1063	7.3	22
32	Hemorrhage and/or Microaneurysm Severity and Count in Ultrawide Field Images and Early Treatment Diabetic Retinopathy Study Photography. *Ophthalmology*, **2017**, 124, 970-976	7.3	38
31	Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. *Ophthalmology Retina*, **2017**, 1, 413-420	3.8	8
30	Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. *Ophthalmology*, **2016**, 123, S78-S88	7.3	73
29	Presence and Risk Factors for Glaucoma in Patients with Diabetes. *Current Diabetes Reports*, **2016**, 16, 124	5.6	48
28	The Future of Ultrawide Field Imaging for Diabetic Retinopathy: Pondering the Retinal Periphery. *JAMA Ophthalmology*, **2016**, 134, 247-8	3.9	14
27	Comparison of Nondiabetic Retinal Findings Identified With Nonmydriatic Fundus Photography vs Ultrawide Field Imaging in an Ocular Telehealth Program. *JAMA Ophthalmology*, **2016**, 134, 330-4	3.9	24
26	Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. *JAMA Ophthalmology*, **2016**, 134, 137-45	3.9	26
25	Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. *JAMA Ophthalmology*, **2016**, 134, 127-34	3.9	42
24	Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening **2016**, 57, 2390-9		17
23	Computational fluid dynamics assisted characterization of parafoveal hemodynamics in normal and diabetic eyes using adaptive optics scanning laser ophthalmoscopy. *Biomedical Optics Express*, **2016**, 7, 4958-4973	3.5	18

22	Identification of Diabetic Retinopathy and Ungradable Image Rate with Ultrawide Field Imaging in a National Teleophthalmology Program. *Ophthalmology*, **2016**, 123, 1360-7	7.3	77
21	Regional Image Features Model for Automatic Classification between Normal and Glaucoma in Fundus and Scanning Laser Ophthalmoscopy (SLO) Images. *Journal of Medical Systems*, **2016**, 40, 132	5.1	24
20	Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema. *Diabetes*, **2015**, 64, 2560-70	0.9	117
19	Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. *Ophthalmology*, **2015**, 122, 949-56	7.3	160
18	Real-Time Ultrawide Field Image Evaluation of Retinopathy in a Diabetes Telemedicine Program. *Diabetes Care*, **2015**, 38, 1643-9	14.6	28
17	Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes. *JAMA Ophthalmology*, **2015**, 133, 525-6	3.9	24
16	Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography. *Ophthalmology*, **2015**, 122, 2465-72	7.3	121
15	Proteomic Analysis of Embryonic and Young Human Vitreous **2015**, 56, 7036-42		12
14	Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. *JAMA Ophthalmology*, **2015**, 133, 888-96	3.9	25
13	Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. *Diabetes*, **2015**, 64, 3588-99	0.9	49
12	Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2137-2146	27.4	423
11	Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. *JAMA Ophthalmology*, **2014**, 132, 1309-16	3.9	264
10	Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. *Ophthalmology*, **2013**, 120, 2587-2595	7.3	158
9	Oral protein kinase c inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C Inhibitor-Diabetic Retinopathy	3.6	82
8	Response to Comment on: Sun et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. Diabetes Care 2011;34:968974. *Diabetes Care*, **2011**, 34, e149-e149	14.6	78
7	Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. *Diabetes Care*, **2011**, 34, 968-74	14.6	174
6	Ruboxistaurin: Review of Safety and Efficacy in the Treatment of Diabetic Retinopathy. *Clinical Medicine Insights Therapeutics*, **2010**, 2, CMT.S5046	0	8
5	Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*, **2010**, 117, 946-53	7.3	72

4	Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. *Journal of Proteome Research*, **2008**, 7, 2516-25	5.6	181
3	Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. *Diabetes Care*, **2007**, 30, 1995-7	14.6	138
2	Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. *Diabetes/metabolism Reviews*, **1997**, 13, 37-50		208
1	Glucose induced genes in bovine aortic smooth muscle cells identified by mRNA differential display. *FASEB Journal*, **1994**, 8, 103-6	0.9	73